Showing papers by "Lee Goldman published in 2009"
TL;DR: A modeling exercise found that the Adult Treatment Panel III guidelines, which recommend treatment based on cholesterol level and estimated coronary heart disease risk, are reasonably cost-effective if statins cost about $1.50 to $2.20 per pill, while treating all persons with LDL cholesterol levels greater than 3.4 mmol/L could be a better strategy.
Abstract: Lipid-lowering therapy is costly but effective at reducing coronary heart disease (CHD) risk. The authors used a probabilistic model to show that the Adult Treatment Panel III guidelines, which rec...
192 citations
TL;DR: Current adolescent overweight will likely lead to large future economic and health burdens, especially lost productivity from premature death and disability, and application of currently available medical treatments will not greatly reduce these future burdens of increased adult obesity.
Abstract: Objectives. We predicted the future economic burden attributable to high rates of current adolescent overweight.Methods. We constructed models to simulate the costs of excess obesity and associated diabetes and coronary heart disease (CHD) among adults aged 35–64 years in the US population in 2020 to 2050.Results. Current adolescent overweight is projected to result in 161 million life-years complicated by obesity, diabetes, or CHD and 1.5 million life-years lost. The cumulative excess attributable total costs are estimated at $254 billion: $208 billion because of lost productivity from earlier death or morbidity and $46 billion from direct medical costs. Currently available therapies for hypertension, hyperlipidemia, and diabetes, used according to guidelines, if applied in the future, would result in modest reductions in excess mortality (decreased to 1.1 million life-years lost) but increase total excess costs by another $7 billion (increased to $261 billion total).Conclusions. Current adolescent overw...
118 citations